Open Forum Infectious Diseases · 2017 · 18 citations · 14 references
PharmacyInfectious DiseasesMolecular VirologyOutcomes ResearchVirologyAntiretroviral TherapyAntiviral PharmacotherapyAntiviral TherapyInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentChronic Viral HepatitisCohort Study InvestigationDirect-acting Antiviral AgentsDirect-acting AntiviralsLong-term Virologic SuppressionSustained Virologic Response DurationTreatment In Coinfected Patients
BACKGROUND: The introduction of direct-acting antivirals (DAAs) created a major paradigm shift in the treatment of chronic hepatitis C. Currently, there is little "real-world" data regarding hepatitis C virus (HCV) treatment outcomes in the human immunodeficiency virus (HIV)/HCV-coinfected population. METHODS: This retrospective cohort study examined HCV treatment outcomes of HIV/HCV-coinfected patients at a large, urban, Ryan White-funded clinic caring for an underserved population. All HIV patients initiating HCV treatment from January 1, 2013 to November 30, 2015 were included in the analysis. The primary end point was sustained virologic response 12 weeks after the end of therapy (SVR12). RESULTS: A total of 172 patients initiated HCV treatment within the study period: 79% were male, 83% were black, 95% were HCV genotype 1, 79% were HCV treatment naive, and 16% had cirrhosis. At baseline, median CD4 was 494 cells/μL (interquartile range, 316-722) and 92% had HIV ribonucleic acid less than 40 copies/mL. The most common DAA initiated was ledipasvir/sofosbuvir (LDV/SOF) (85%), with 92% receiving 12 weeks of treatment. Overall, SVR12 was 93% by intention-to-treat analysis and 98% by per-protocol analysis. The majority of patients on LDV/SOF did not report any adverse effect. One patient in the ribavirin plus SOF group discontinued treatment due to adverse effect. CONCLUSIONS: In a cohort of mainly black, male, HIV/HCV-coinfected patients at a large, urban, Ryan White clinic, HCV treatment with DAAs resulted in high SVR12 rates and was well tolerated despite real-world challenges including medication access barriers and drug interaction concerns.
14
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie, Curtis Cooper, Michael S. Saag et al. · New England Journal of Medicine · 2015 · 467 citations · Full text
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David Wyles, Peter Ruane, Mark Sulkowski et al. · New England Journal of Medicine · 2015 · 422 citations · Full text
Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark Sulkowski, Susanna Naggie, Jacob Lalezari et al. · JAMA · 2014 · 254 citations · Full text